SLXNWNCM

Silexion Therapeutics Corp

+27.0% · 90d

$0.03

+0.00 (+0.00%)

News

No News Yet

Press releases and SEC filings for SLXNW will appear here as they are published.

Check back later for updates

Key Data

Market Cap—

Open$0.03

Prev Close$0.03

Day Range$0.01 – $0.03

52W Range$0.01 – $0.03

Volume20,842

P/E (TTM)—

EPS—

Dividend Yield—

Beta0.06

About

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

13 employees

silexion.com

Top Institutional Holders

As of 2025-12-31 · prior 2025-09-30

DeepCurrents Investment Group LLC$27,231

14,183 sh0.0%

Oasis Management Co Ltd.$21,333

11,111 sh0.0%

Polar Asset Management Partners Inc.$19,330

743,475 sh0.0%

Linden Advisors LP$8,573

337,500 sh0.0%

ARISTEIA CAPITAL, L.L.C.$6,292

236,546 sh0.0%

See all holders →

Quarterly Financials

09/25

Revenue Net Income